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Abstract
Background—Many of the complications encountered during diabetes can be linked to the non-
enzymatic glycation of proteins, including human serum albumin (HSA). However, there is little
information regarding how the glycation pattern of HSA changes as the total extent of glycation is
varied. The goal of this study was to identify and conduct a semi-quantitative comparison of the
glycation products on HSA that are produced in the presence of various levels of glycation.
Methods—Three glycated HSA samples were prepared in vitro by incubating physiological
concentrations of HSA with 15 mmol/l glucose for 2 or 5 weeks, or with 30 mmol/l glucose for 4
weeks. These samples were then digested and examined by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-TOF MS) to identify the glycation products
that were formed.
Results—It was found that the glycation pattern of HSA changed with its overall extent of total
glycation. Many modifications including previously-reported primary glycation sites (e.g., K199,
K281, and the N-terminus) were consistently found in the tested samples. Lysines 199 and 281, as
well as arginine 428, contained the most consistently identified and abundant glycation products.
Lysines 93, 276, 286, 414, 439, and 524/525, as well as the N-terminus and arginines 98, 197, and
521, were also found to be modified at various degrees of HSA glycation.
Conclusions—The glycation pattern of HSA was found to vary with different levels of total
glycation and included modifications at the 2 major drug binding sites on this protein. This result
suggests that different modified forms of HSA, both in terms of the total extent of glycation and
glycation pattern, may be found at various stages of diabetes. The clinical implication of these
results is that the binding of HSA to some drug may be altered at various stages of diabetes as the
extent of glycation and types of modifications in this protein are varied.
Keywords
Non-enzymatic glycation; human serum albumin; diabetes; matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry; glycation-related modifications
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1. Introduction
The glycation of various proteins in the body is accelerated during diabetes [1]. This
process, known as the Maillard reaction, involves the addition of reducing sugars and/or
their degradation products to free primary and secondary amine groups on proteins [2,3].
The first step of this reaction involves the nucleophilic addition of a reducing sugar to a
primary amine group (e.g., as found on a lysine or at the N-terminus of a protein). In this
stage a reversible Schiff base is formed which can undergo a slow irreversible
rearrangement to form more stable Amadori products that accumulate over time. The total
amount of accumulation of these products is known to be dependent on the type of sugar
that is causing the glycation [4], the incubation time and sugar concentration [5], and the
type protein that is being modified [6–8].
The Maillard reaction is fairly well-characterized for proteins with long lifetimes in the body
(e.g., collagen [9–12] and lens crystalline [13–15]) and for some proteins with shorter half-
lives (e.g., hemoglobin [16–18]). However, until recently there has been little information on
this process for human serum albumin (HSA) [8], which is the major carrier agent for many
drugs and small endogenous solutes in blood [2,19]. HSA has 2 major binding regions for
drugs. These sites are known as Sudlow sites I and II and are located in subdomains IIA
(within residues 150–292) and IIIA (within residues 384–489) of HSA, respectively [2,20].
Previous studies have found that glycation can alter the interactions of HSA with certain
solutes [21–23] and may, under certain conditions, affect the overall structure of HSA
[24,25]. It is expected from these observations that characterization of the modifications that
occur on HSA would be valuable in helping determine why such changes in binding can
occur during glycation.
Previous studies with glycated HSA prepared under specific conditions have indicated that
the most significant sites for early glycation are the N-terminus and lysines 199, 281, 439,
and 525 [2,26,27]. Similar work looking at modification of HSA with methylglyoxal has
identified certain regions that are prone to advanced glycation end product (AGE)
modification [28], including arginine 410 as a major region of modification and arginines
114, 186, 218, and 428 as regions with smaller amounts of modification. These findings are
consistent with recent qualitative [29] and quantitative studies [30] that have been conducted
by our group using minimally-glycated HSA. However, no past studies have looked at how
these glycation patterns are altered when comparing samples of HSA with different levels of
glycation.
In this study, HSA with various levels of glycation will be prepared in vitro under solution
conditions and reaction times that are similar to those found for HSA in serum during
diabetes [31,32]. The modifications that occur on the resulting samples of glycated HSA will
be examined by using matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) [33]. A comparison will then be made between the results
obtained for the HSA made with different extents of glycation and with previous results
reported for minimally glycated HSA [29,30]. The modifications that are found will also be
compared to the known locations of the major drug binding sites on HSA. This data should
provide a more complete picture of how the structure of HSA and its function as a carrier
agent for drugs are affected by various stages of glycation during diabetes.
2. Materials and methods
2.1. Materials
The HSA (99% pure, essentially fatty acid and globulin free), guanidine-HCl (99%),
ammonium bicarbonate (99%), tris-HCl (99%), α-cyano-4-hydroxycinnamic acid (CHCA,
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99%), 2,3-dihyroxybenzoic acid (DHB, 98%), dithiothreitol (99%), iodoacetamide (99%),
D-glucose (99%), sodium azide (99%), trifluoroacetic acid (TFA, 98%), formic acid (96%),
molecular biology grade water (DNase, RNase, and protease free), methanol (HPLC grade,
99.9%), acetonitrile (HPLC grade, 99.9%), and sequence-grade trypsin, Glu-C or Lys-C
were all purchased from Sigma-Aldrich (St. Louis, MO). The enzymatic assay used to
determine the overall degree of glycation for HSA was purchased from Diazyme
Laboratories (Poway, CA).
2.2. Apparatus
Siliconized low retention microcentrifuge tubes (0.6 ml and 1.5 ml volume), Slide-A-Lyzer
dialysis cassettes (7 kDa cut off, 0.1–0.5 ml and 0.5–3 ml sample volumes), μ-C18 Zip-tip
pipette tips (0.2 μL bed volume), 0.20 μm nylon filters, and 10 DG size exclusion columns
(10 ml volume) were obtained from Fisher Scientific (Pittsburgh, PA). The Speedvac used to
concentrate protein samples was from Savant Instruments Inc (Farmingdale, NY). Mass
spectra were acquired on a Voyager 6148 MALDI-TOF MS system (Applied/Perspective
Biosystems, CA). A positive ion delayed extraction mode was used on this system with an
accelerating voltage of 25 kV, a grid wire voltage which was 0.008% of the accelerating
voltage, a grid voltage which was 77% of the accelerating voltage, and a delay time of 100
ns. Matlab 2009a, including the bioinformatics toolbox, was purchased from Mathworks
(Natick, MA). Mascot wizard was obtained from the Matrix Science website [34].
2.3. Preparation of glycated HSA
Glycation was initiated by incubating a physiological concentration of HSA (42 g/l) with a
15 mmol/l glucose solution. The glucose solution was prepared in pH 7.4, 200 mmol/l
phosphate buffer which also contained 1 mmol/l sodium azide (Note: sodium azide was
added to prohibit bacterial growth; this agent is toxic, and care must be used to avoid contact
of this compound with skin [35–37]). HSA samples containing 3 different levels of total
glycation were examined. To make these samples, the starting HSA/glucose solution was
divided into several portions and incubated at 37 °C for 2–5 weeks [38], which gave the
“HSA-2” and “HSA-5” samples used in this report. A control sample was prepared under
identical conditions by using a solution of 42 g/l HSA dissolved in the same pH 7.4 buffer
with sodium azide (but without the addition of glucose) and that was incubated for five
weeks at 37 °C. A third glycated HSA sample was prepared under these conditions but with
a total added glucose concentration of 30.7 mmol/l (i.e., representing hyperglycemic
conditions [37]) and an incubation time of 4 weeks; these conditions provided the “HSA-4”
sample used in this report. A second control sample of HSA was also prepared under these
latter conditions in the absence of any glucose.
Each sample of glycated HSA was isolated from its reaction mixture by using size-exclusion
chromatography and equilibrium dialysis. First, a 10 DG size exclusion column was washed
with 20 ml of water, followed by the application of 3 ml of the desired glycated HSA
solution. A 5 ml portion of water was passed through the column to elute the glycated HSA
and this fraction was collected. A 2.5 ml aliquot of this fraction was transferred to a 0.5–3
ml dialysis cassette and dialyzed extensively against two 1000 ml portions of water for 2 h
at room temperature. An additional dialysis step against 1000 ml water was performed
overnight at 4 °C. The glycated HSA solution was then removed from the dialysis cassette,
lyophilized, and stored at 4 ºC until later use. A modified commercial fructosamine assay kit
was used to determine the level of HSA glycation [39]. In this assay, glycated proteins were
cleaved into protein fragments using proteinase K, and the fructosamine residues were
specifically targeted by fructosaminase to produce amino acids and H2O2. The resulting
H2O2 was then detected by using a colorimetric peroxidase-linked reaction [40,41]. None of
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the AGEs examined in this report have been reported by the manufacturer of the kit to create
interferences in this method.
2.4. Pretreatment and digestion of HSA
The glycated HSA samples and control samples were pretreated and digested using the same
procedure, equipment and reagents to minimize any differences in digestion patterns due to
changes in experimental conditions. Prior to pretreatment of the HSA, molecular biology-
grade water was used to prepare a pH 8.5, 100 mmol/l ammonium bicarbonate buffer.
Solutions containing 6 mol/l guanidine-HCl or 1 mol/l dithiothreitol reagent were prepared
using this ammonium bicarbonate buffer. A solution containing 1 mol/l iodoacetamide and 1
mol/l sodium hydroxide was prepared in water. A 1 ml solution of 3 mg/ml HSA was
prepared in the guanidine-HCl solution and was gently mixed. A 15 μl aliquot of DTT
reagent was then added to the HSA solution. This mixture was incubated at 37 °C for 1 h,
after which 36 μl of the iodoacetamide/sodium hydroxide reagent was added to the HSA
solution. The resulting solution was incubated in the dark at room temperature for 30 min.
Following this incubation, an additional 150 μl of the DTT reagent was added to the
mixture. The HSA solution was then divided into 0.5 ml portions that were placed into 0.1–
0.5 ml dialysis cassettes. Dialysis was performed on the contents of each cassette against
three 1000 ml portions of water, where each dialysis cycle was performed for 4 h at room
temperature. The dialyzed HSA samples were divided into 50 μl aliquots, each containing
about 100 μg HSA, and placed into low-retention microcentrifuge tubes. These aliquots
were reduced to dryness and stored at −80 °C.
Stock enzyme solutions containing 1 mg/ml of trypsin, Lys-C, or Glu-C were prepared in
water. A pH 7.8, 100 mmol/l ammonium bicarbonate buffer and a pH 9.0, 75 mmol/l Tris-
HCl buffer were also prepared. For the trypsin digest, 200 μL of ammonium bicarbonate
buffer was added to vials containing pretreated HSA/glycated HSA. Each vial of the
reconstituted HSA was mixed for 3–5 min, with a 3.3 μl portion of the trypsin stock solution
then being added to each reconstituted HSA sample, giving a substrate-to-enzyme ratio of
30:1. These solutions were incubated at 37 °C for 18 h; a 10 μl aliquot of concentrated
formic acid was added to each HSA solution and the resulting HSA digests were stored at
−80 °C. For the Glu-C digest, 200 μL of a pH 7.8, 100 mmol/l ammonium bicarbonate
buffer was added to vials containing pretreated HSA/glycated HSA, and this mixture was
mixed for 3–5 min. A 10 μl portion of the Glu-C stock solution was added to each HSA
sample and the solutions were incubated at 37 °C for 8 h. Another 5 μl portion of the Glu-C
stock solution was added to each HSA sample, giving a final substrate-to-enzyme ratio of
7:1, and the resulting solutions were incubated for an additional 18 h. A 10 μl aliquot of
concentrated formic acid was added to each digests and the resulting solutions were stored at
−80 °C. For the Lys-C digest, 200 μL of pH 9.0, 75 mmol/l tris-HCl buffer was added to
vials containing pretreated HSA/glycated HSA, and these vials were mixed for 3–5 min. A 5
μl portion of the Lys-C stock solution was added to each vial of HSA and the resulting
mixtures were incubated at 37 °C for 18 h. A 10 μl aliquot of concentrated formic acid was
added to the digests, and the final solutions were stored at −80 °C.
2.5 Collection and analysis of mass spectra
A MALDI matrix that contained both CHCA and DHB was prepared as described
previously [30]. A stock calibration mixture containing 32.5 pmol/l glufibrinopeptide
(1570.6774 Da), 25 pmol/l des-Arg-bradykinin (904.4681 Da), and 32.5 pmol/l angiotensin I
(1296.6853 Da) was prepared in 100% acetonitrile. The MALDI matrix was spiked by
adding 4 μL of the stock calibration mixture to 96 μl of the matrix. This spiked matrix
solution was placed on every other row of a 96-well MALDI-TOF MS plate in positions that
were adjacent to those used for the HSA samples. μ-C18 Zip-tips were used to fractionate the
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peptide digests [33]. A 1 μl aliquot of the fractionated peptides was mixed with 1 μL of the
spiked matrix solution and 0.80 μl of the resulting mixture was spotted onto a 96-well
MALDI-TOF MS plate. All of the mass spectra acquired in this study were first externally
calibrated using the calibration spots on the adjacent rows to the samples. These spectra
were then internally calibrated by using the spiked calibrant masses found in the mass
spectra for the HSA samples.
An evaluation of unspiked HSA samples indicated that there was no overlap in the m/z
values for the calibrants and the detected HSA-derived peptides. A maximum allowable
difference (or error) of 25 ppm in the measured masses, representing 2 times the precision of
the experimentally-measured mass deviation for unmodified peptides, was found to be
sufficient for matching the actual and predicted peptide masses when this technique was
used [42]. Programs written in Matlab were used to assist in the data analysis (Note: Copies
of these programs are available upon request). Raw mass values from each mass spectrum
were extracted using Mascot Wizard and these values were compared to an expanded
modification list (see Table 1) that was generated by using a program written in Matlab.
Only unique peptides that were found in HSA-2, HSA-4, or HSA-5 samples were matched
to this search list. To determine which peptides were unique, a separate Matlab program was
used to compare the extracted mass list for the glycated HSA samples versus the control
HSA samples and to match those masses within 50 ppm. The peaks in the glycated sample
that did not match were selected for further analysis. During this process, any modified
peptides with masses that matched predicted values within 25 ppm were considered to
potentially contain glycation-related adducts.
3. Results and discussion
2.5. Control of extent of glycation and determination of sequence coverage
Figure 1 shows how the extent of glycation of HSA, as measured by a fructosamine assay,
changed over time during the in vitro preparation of this modified protein. These results
were obtained for the reaction of 42 g/l HSA with 15 mmol/l glucose at pH 7.4 and at 37 °C
over six weeks. Most of the increase in glycation occurred during the first three weeks, with
the rate of glycation slowing down between three and six weeks. Similar trends have been
noted in previous work examining the incubation of HSA [43] or bovine serum albumin
with glucose [37]. Two of the samples selected for more detailed analysis were prepared
under these conditions using two or five weeks of incubation (i.e., the samples referred to as
“HSA-2” and “HSA-5” in this report). These conditions were used to obtain glycated HSA
that was similar in its glycation levels to that found in serum during pre-diabetes or typical
diabetes. A third sample was prepared by incubating 42 g/l HSA with 30 mmol/l glucose for
four weeks. This sample was used to represent higher levels of glycation, as might occur in
advanced or uncontrolled diabetes. An assay of these samples gave the following measured
levels of glycation: HSA-2, 0.72 (± 0.1) mol hexose/mol HSA; HSA-5, 1.23 (± 0.1) mol
hexose/mol HSA; and HSA-4, 3.35 (± 0.1) mol hexose/mol HSA. These levels of
modification were similar to the range of HSA glycation that is typically found in vivo
during diabetes (i.e., 1–3 mol hexose/mol HSA) [44]. A similar assay of the original HSA
and control sample that was used to prepare these glycated samples was found to have no
measurable level of fructosamine (i.e., less than 0.02 mol hexose/mol HSA).
Details on the sequence coverage that was obtained for the HSA and glycated HSA samples
are provided in the Supplemental Information. For the control HSA sample, the tryptic, Lys-
C and Glu-C digests covered 78%, 47% and 56% of the primary sequence of HSA,
respectively. Similarly, digestion of the HSA-2 sample with the same enzymes gave
sequence coverages of 63%, 49% and 44%; the HSA-5 sample gave 54%, 44% and 49%
sequence coverages; and the HSA-4 sample had sequence coverages of 69%, 45%, and 55%.
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When the results of these digests were combined, the total sequence coverages for the
control HSA, HSA-2, HSA-4, and HSA-5 samples were 90%, 81%, 84%, and 82%,
respectively. A decreased coverage for the glycated HSA samples versus the control HSA
was expected because glycation would reduce the amount of unmodified peptides and
decrease the signal for some of these peptide below the selected signal-to-noise ration of
detection (i.e., S/N = 5, in this case). The coverage for the HSA-2, HSA-4 and HSA-5
samples all increased to approximately 85% when assigned glycated adducts were factored
into the sequence coverage calculation.
For the control sample and the glycated samples, all of the arginine residues in HSA were
included in this sequence coverage. For the control sample, 83% of the lysine residues were
included, with the exception of lysines 4, 233, 240, 317, 534, 536, 538, 541, 545, and 560.
Similarly, 81% of the lysines in the HSA-2 sample were included, with the exception of
lysines 136, 233, 240, 313, 317, 323, 359, 534, 536, 538, and 560. Lysines 4, 541, and 545,
which were not covered in the control HSA sample, were covered in the HSA-2 sample. For
the HSA-5 sample, 76% of the lysines were part of the sequence coverage, with the
exception of lysines 233, 240, 262, 313, 323, 317, 351, 359, 444, 536, 538, 541, 545, and
560. Lysines 4 and 534, which were not covered in the control HSA sample, were covered in
the HSA-5 sample. For the HSA-4 sample, 85% of the lysines were covered, excluding
lysines 233, 240, 323, 359, 534, 536, 538, 541, and 545. Lysines 4, 317, and 560, which
were not covered in the control HSA sample, were covered in the HSA-4 sample. The lack
of coverage for these regions of HSA was of limited consequence in this study because none
of these residues have been found in earlier work to have major amounts of modification on
glycated HSA [26,28] (Note: minor modifications have been noted previously for lysines
136, 233, 323, 351 or 359, and 536 or 538 [29]).
2.6. Identification of glycation products
The glycation products formed on HSA were identified by first determining the peptide ions
with mass values that were unique to the glycated HSA samples. The modifications in these
ions were then determined by comparing these mass with a theoretical list of modified
peptides that might result from a glycated HSA digest. When this approach was used,
several early and late-stage glycation adducts were assigned to the glycated HSA samples
(see Table 2). For the HSA-2 sample, 8 peptides were found to be modified to form a
mixture of early glycation products and AGEs. Similarly, 8peptides were found to be
modified to produce glycation products in both the HSA-4 and HSA-5 samples.
One feature that was used for glycation site assignment was the fact that modifications could
not occur on the same amino acids that were acting as cleavage sites for trypsin or Lys-C
[29,45]. This fact allowed for the unambiguous assignment of glycation products to three
peptides in the HSA-2 sample. These three peptides encompassed regions 1–10, 196–205,
and 275–286 on HSA and corresponded to changes in mass (Δm) of 414, 306, or 306 Da
respectively. The peptide encompassing residues 1–10 was found to be modified to form
dehydrated fructosyl-lysine (FL-1H2O), which is specific for lysines, and 1-alkyl-2-
formyl-3,4-glycosyl-pyrrole (AFGP), which can be formed on either lysine or arginine
residues. This peptide contained the N-terminus (N+), K4 and R10 on HSA. Thus, the
observed modifications were occurring on N+ or K4 because the C-terminal end of R10 was
being cleaved by trypsin. Modifications by AFGP plus Nε-[5-(2,3,4-trihydroxybutyl)-5-
hydro-4-imidazolon-2-yl]ornithine (3-DG-H1) or tetrahydropyrimidine (THP) would also
give a Δm value of 414 Da. However, 3-DG-H1 and THP are arginine-specific
modifications, making them less likely to have been present.
The peptide containing 196–205 in the HSA-2 sample was found to be modified by FL plus
3-DG-H1 or THP. A modification by THP or 3-DG-H1 would result in the same change in
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mass and could not be differentiated based solely on the Δm values. This peptide contained
K199, R197, and K205, but the C-terminal end of K205 was cleaved by trypsin. This
indicated that the most likely sites of modification on this peptide were at R197 and K199,
which formed THP/3-DG-H1 and FL, respectively. A Δm value of 306 Da could also have
been produced by the presence of both FL and FL-1H2O; however, the presence of these
combined changes was unlikely because it would require that both K199 and K205 (which
was cleaved by Lys-C) were being modified. Similarly, for residues 275–286 in the HSA-2
sample both K276 (FL or FL-1H2O) and K281 (FL or FL-1H2O) were assigned as
modification sites.
There were several residues in both the HSA-4 and the HSA-5 samples that could be
assigned with a high level of certainty because of the pattern of missed cleavage points that
was observed. For instance, residues 520–525, 275–286, 5–20, and 525–534 were found to
be modified to form pyrraline (Pyr) plus Nε-(5-hydro-4-imidazolon-2-yl)ornithine (G-H1)
(Δm = 148 Da), FL + FL-1H2O (Δm = 306 Da), FL (Δm = 162 Da), and FL-1H2O (Δm =
144 Da), respectively, in the HSA-5 sample. Residues 275–286 were found to have identical
modifications (i.e., forming FL + FL-1H2O) in both the HSA-2 and HSA-5 samples, which
indicated that this region had a high propensity for the creation of such adducts.
Modifications were assigned to K524 (Pyr) and R521 (G-H1), K12 (FL), and K525
(FL-1H2O) within these peptides based on the expected pattern of missed cleavage points
for Lys-C and trypsin. The same approach was used to assign modifications in the HSA-4
sample for residues 258-274, 312–321, and 83–100, which were found to form FL-1H2O
(Δm = 144 Da) at K262, AFGP + AFGP(Δm = 540 Da) at K313 and K317, and FL-2H2O or
Nε-carboxyethyl-lysine (CEL) at K93 plus MG-H1 (Δm = 126 Da) at MG-H1, respectively.
2.7. Computational analysis of glycation sites
The pKa of a given amino acid residue, the fractional accessible surface area of this residue,
and the location of the residue relative to local catalytic sites (i.e., histidines or lysines) were
all used to help compare the expected reactivity of lysines and/or arginines during glycation.
For this analysis, lysines that were within 15 Å of other positively-charged groups in the
crystal structure of HSA were considered to have a higher amount of reactivity versus other
lysines on HSA [26]. In this previous study, the proximity of lysine residues to histidine
residues on albumin, particularly in regions close to disulfide bonds, was found to influence
the level of total glycation at these sites. This observation was the rational for using a
distance-based approximation based on the known crystal structure of HSA and Visual
Molecular Dynamics [46,47], along with the information provided by MALDI-TOF MS, as
an initial computational approach to help identify the most reactive regions of HSA during
glycation. Although some small differences may be present between the crystal structure of
HSA and the structure of this protein’s soluble form when doing these calculations, the
information this approach provided was still found to be useful as an initial tool in
comparing the expected reactivities of various residues to glycation.
Arginines and lysines that had low pKa values versus other lysines/arginines on HSA, as
estimated using PROPKA [48], were also used with the MALDI-TOF MS data as a second
computational approach to help identify sites on HSA that were susceptible to glycation-
related modifications. When information about local catalytic sites or pKa values did not
provide insight as to the likelihood of modification at a given residue, computational results
using the fractional accessible surface area (FAS) of the residues were also used as
indicators of reactivity. This overall approach has been shown in previous work with
MALDI-TOF MS, quantitative proteomics and minimally-glycated HSA to be valuable in
helping identify possible glycation sites [30]. A more detailed discussion of these
computational techniques is given in the Supplemental Information. These computational
approaches were employed in this study in cases where multiple lysines or arginine residues
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were present on the same peptide or when several modified peptides had mass-to-charge
ratios within the allowed mass accuracy that could be associated with a given peak in the
mass spectra for glycated HSA.
The HSA-4 digest contained four peptides for which computational methods were used to
determine the most likely modification sites. The majority of these peptides were from the
Glu-C digest, which had no cleavage specificity for lysines or arginines. In the HSA-4 Glu-
C digest, residues 557–571, 426–442, and 189–208 were found to form FL + CML (Δm =
220 Da), FL or Pyr + MG-H1 (Δm = 162 Da), and Pyr + IB (Δm = 250 Da), respectively.
Residues 557–571, which was modified to form two lysine-specific adducts, contains K557,
K560, and K564. K560 and K564 are located near a disulfide bridge (C558 and C567),
which places these two residues within 11 Å of each other. K557 is not located within 25 Å
of any basic amino acids, which indicated that the formation of any glycation products at
this residue would not have been enhanced by local acid-base catalysis. The proximity of
K560 and K564 to each other suggested that these residues were more likely to form FL and
CML. These residues also had large FAS values of 0.82 and 0.72, respectively, versus a
FAS value of 0.68 for K557. These results all indicated that K560 and K564 were the most
likely modification sites within residues 557–571.
Lysine 439 was tentatively determined to be the most reactive site within residues 426–442
in both the HSA-4 and HSA-5 samples, as based on the location of this residue relative to
H440 (3.83 Å) in a loop region of HSA. This result indicated that K439 was being modified
to form FL or Pyr in the HSA-4 sample and Pyr or CEL in the HSA-5 sample. The
assignment of modifications to K414 (FL-1H2O or AFGP) and R428 (AFGP and 3DG-H1/
THP) was made without the use of computational data, with these modifications being found
in both the HSA-2 and HSA-5 samples. This information suggested that the region spanning
residues 414–442 of HSA had a strong tendency to be modified during glycation. R428 was
found to be modified in residues 414–432 and 426–442, indicating this arginine was
particularly prone to modification, in agreement with a previous study examining the
formation of HSA adducts with methylglyoxal [28]. Residues 189–208 were found to be
modified to form Pyr + IB in both the HSA-4 and HSA-5 samples. In this case the
assignment of IB to R197 could be made without the use of computational data, and K199
was found to be modified by Pyr, as determined based on the proximity of K199 to H247
(15.19 Å) and its relatively low pKa value of 7.47. This latter result agrees with previous
work examining glycation-related modifications that occur at K199 [26].
In situations where a particular modification site could not be identified based on
computational data, a comparison with the previous results in the literature was conducted
[25–27]. For instance, an ion with a mass of 1622 Da that was identified in the HSA-4 digest
could have been produced by modifications occurring on residues 1–12 (CEL + FL-2H2O or
FL-1H2O + MG-H1, Δm = 198 Da), 200–212 (CML + ArgP, Δm = 138 Da), or 403–413
(AFGP, Δm = 270 Da). The N-terminus and K4 in residues 1–10 were determined to be the
most likely sites of modification in this case because the N-terminus has previously been
identified as a glycation site on HSA [2,27], and K4 was located beside H3 (i.e., which
would have enhanced the rate of glycation products at this residue). The corresponding
modifications at these residues were CEL and FL-2H2O. Similarly, modifications occurring
at K199 (to form AFGP, FL, or Pyr) and K205 (to form AFGP, FL, or Pyr) in the HSA-4
sample were determined to be the most likely source of the observed ion with a mass of
1707 Da because these lysines were located close to H247 and H242, respectively, which
would have enhanced the formation of glycation products [26].
Two modified peptide ions with masses of 2409 and 2547 Da were identified in the HSA-2
sample. The first of these two peptides represented modifications on either residues 539–557
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(FL-2H2O + FL-2H2O, FL-1H2O + Pyr, Δm = 252 Da) or 542–560 (FL-2H2O + Pyr, FL +
CEL, Δm = 234 Da) and the second was due to modifications on residues 566–585 (AFGP +
AFGP, Δm = 540 Da) or 168–188 (FL + ArgP, Δm = 242 Da). The assignment of
modifications on these particular peptides was difficult because there was no clear indicator
of the amino acid reactivity from either computational analysis or the literature to help in
this assignment.
2.8. Semi-quantitative analysis of glycation sites
There were several cases in this study in which a given lysine or arginine residue was found
to be modified in multiple samples, such as in different digests of a particular glycated HSA
sample or in HSA samples representing different stages of glycation. In these cases, the
number of times that a given residue was found to be modified was used as a semi-
quantitative indicator of the reactivity of that particular residue with regards to glycation. A
structure of HSA that includes these semi-quantitative assignments is given in Figure 2. In
this structure, 6 regions of HSA were found to be modified to form at least 2 glycation
products.
The highest amount of modification was found in regions 196–209, 278–294, and 414–442
of HSA. Four peptides were modified within region 196–209 when all stages of glycation
were considered: one modified peptide (196–205) in the HSA-2 sample, 2 modified peptides
in the HSA-4 sample (189–208 and 198–209), and one modified peptide (189–208) in the
HSA-5 sample. All of these peptides had a modification assigned to K199. This result
indicated that K199 was prone to glycation for in vitro glycated HSA, in agreement with
previous studies that have found this residue to be a major glycation site on HSA [26,29]. It
was also found that K199 was modified by FL in the early stages of glycation (i.e., in
HSA-2), while Pyr, and FL-1H2O or FL-2H2O appeared to be the dominant modifications at
this location during later stages of glycation (i.e., in HSA-4 and HSA-5). This result was not
surprising considering the increased amount of AGEs that would occur as a protein like
HSA is subjected to glycation over long periods of time [5,49]. A large number of
modifications were also assigned in this study to R197. For this site, the predominant adduct
that was formed was either 3-DG-H1 or THP in the early stages of glycation (i.e., HSA-2
sample) or IB in later stages of glycation (i.e., the HSA-4 and HSA-5 samples). An identical
modification of R197 to form 3-DG-H1 or THP has been identified in a previous study using
a commercial preparation of minimally-glycated HSA [29].
Four modified peptides from region 278–294 of HSA were found when all stages of
glycation were considered. In this case, residues 278–292 were modified in the HSA-2
sample, residues 281–294 were modified in the HSA–5 sample, and residues 275–286 were
modified in both the HSA-2 and HSA-5 samples. K281 was modified in all four peptides to
form FL-related modifications, CEL, and/or Pyr. The identification of K281 as a major
modification site is consistent with data from other reports using both in vitro and in vivo
glycated HSA [26,29]. It was found that there were also minor contributions from
modifications at K276 and K286 within residues 278–294 to form FL or FL-1H2O and FL,
FL-2H2O, CEL, or Pyr, respectively.
Residues 414–442 on HSA were found to contain at least four modified peptides, as noted in
all of the glycated HSA samples. R428 was identified as a modification site in all four of
these peptides and was involved in the formation of a number of AGEs (AFGP or 3-DG-H1/
THP, ArgP or G-H1, and MG-H1), depending on the level of total glycation. There were
also minor modifications at K414 (FL-1H2O or AFGP) and K439 (Pyr or CEL, and FL or
CEL) within region 414–442 of HSA. These findings are again consistent with previous
reports, in which R428 [28] and K439 [26,29] have been identified as prominent
modification sites on HSA. Several modifications were also found at the N-terminus
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(FL-1H2O, FL-2H2O, AFGP, and/or CEL) and K525 (FL-1H2O), both regions of which
have been identified as having high levels of modification in other studies [2,26,27,29].
The glycation sites noted in this report were compared to modification regions that have
been previously identified using commercial preparations of minimally glycated HSA
[29,30]. These comparisons were made based on 1) qualitative data using shifts in peptide
masses [29] and 2) data based on quantitative proteomics and 16O/18O-labeling [30]. The
results obtained from this analysis are summarized in Table 3. Seven of the modified
peptides that were found in this current study to have high levels of modification were also
found to be modified in previous studies [29,30]. Three of these modified peptides contained
K525, K439, or K199, which are also the residues expected from prior work to have high
levels of modification in glycated HSA [2]. In addition, K12 R81, R197, R428, K205, K286,
and K524 were all identified as modification sites in both this report and in previous studies
using glycated HSA [29,30].
3.5 Physiological relevance of results
The physiological and pathological relevance of the changes in glycation patterns that were
seen in this study can be demonstrated by comparing these results with recent solute binding
studies that have used similar samples of glycated HSA. In one such study, the association
equilibrium constant for L-tryptophan, an essential amino acid that binds to Sudlow site II
on HSA, had up to a 5.8-fold increase in affinity in going from normal HSA to in vitro
glycated HSA that was prepared in the same manner as used in this study [39]. Using the
same preparations of glycated HSA as in Ref. [39], the sulfonylurea drug tolbutamide (i.e.,
which has been used in the treatment of type II diabetes) was found to have up to a 1.3- to
1.4-fold increase in its association equilibrium constants at Sudlow sites I and II in going
from normal to glycated HSA [50]. These changes in binding strength with the level of
glycation clearly indicate that such modifications can alter interactions of drugs and other
solutes with HSA, which in turn could change the effective activity and transport of these
agents in the circulation [39,50,51].
The need to consider how changes in glycation patterns may vary with the extent of
glycation is demonstrated by a similar binding study for the sulfonylurea drug
acetohexamide [51]. This binding study used the same preparations of in vitro glycated HSA
[39,50] and similar preparations to those utilized in this report. Acetohexamide gave an
overall increase in binding affinity to HSA as the level of glycation increased but different
local changes in binding strength at Sudlow sites I and II. At Sudlow site I, there was a 40%
increase in the association equilibrium constant when going from normal HSA to mildly
glycated HSA (i.e., a sample similar to HSA-2). This change was followed by a decrease in
affinity for HSA with higher amounts of glycation and that was identical to the HSA-4
sample examined in this current report. In the case of Sudlow site II, the binding of
acetohexamide to the same samples of glycated HSA showed a 40% decrease in affinity at
low levels of modification, followed by an increase in affinity at higher levels of glycation.
This trend fits the observations made in this current report in that the modifications at
Sudlow site I for residues 278–292 (FL, CEL, and/or Pyr), and 196–205 (FL, 3-DG-H1)
appeared to transition to dehydrated FL and CEL (281–294), and Pyr and IB (196–205) in
the more highly glycated sample (HSA-5).
In this report, residues 414–432 at Sudlow site II were found to be modified by
combinations of FL-1H2O and AFGP or AFGP and 3-DG-H1/THP in the HSA-2 and
HSA-5 samples. Residues 426–442 were only found to be modified in the HSA-5 sample,
giving mixtures of G-H1 and Pyr or ArgP and CEL. The HSA-4 sample, which contained
the highest amount of glycation in this current study and in the previous binding studies with
acetohexamide and tolbutamide [50,51], appeared to have a smaller number of modifications
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at Sudlow site II, with only a single modified peptide (i.e., residues 426–432 containing FL
or Pyr+MG-H1) being detected at this site and in this sample. These changes in the number
and types of modifications as the extent of glycation was varied suggest that 1) the changes
in binding affinity seen for acetohexamide and tolbutamide during glycation [50,51] are
related to the relative rates of formation and accumulation of the various possible
modifications, and 2) different modifications may affect this binding to different degrees.
Further studies based on quantitative proteomics and mass spectrometry are now being
conducted to further characterize these changes in structure. However, the correlation
already been noted between the structural and functional information indicates that the
glycation level of HSA can affect its binding to pharmaceutical agents, including drugs such
as acetohexamide and tolbutamide that are used to treat diabetes.
3. Conclusion
In this report, regions 189–209, 275–294, and 414–442 of HSA all appeared to be
particularly prone to modification as a result of glycation. Two of these regions (189–209
and 275–294) are located within Sudlow site I, which is a major drug binding site on HSA
[2]. Lysine 199, which has repeatedly been identified in the past as a modification site
within this highly glycated region of HSA, is also known to be directly involved in the
interactions of many drugs and fatty acids with HSA [2,52]. Lysine 281 was also found to
have high levels of modification during glycation; this residue is located in the structure of
HSA at a location that is only 13 Å away from a known ligand binding residue within
Sudlow site I [46]. Residues R428, K414, and K439, which were all found to have high
levels of modifications in the glycated HSA samples, are located within Sudlow site I, the
second major drug binding site of HSA [46].
The close vicinity of these modification sites to known drug binding sites on HSA helps
explain why glycation may alter the interaction of many drugs and solutes that bind to
Sudlow site I on HSA. For instance, the binding of bilirubin at Sudlow site I, has been
shown to be altered when comparing normal HSA to in vivo glycated HSA [25]. In addition,
binding by drugs such as phenytoin and valproate, which can involve multiple sites on HSA)
[53] has been shown to be affected by glycation in diabetes [54]. It has also been shown
previously that the binding of several solutes at Sudlow site II can be altered when using
glycated HSA [21,28,38].
A semi-quantitative analytes of glycation adducts that were found in this report indicated
that the N-terminus, lysines 93, 199, 276, 281, 286, 414, 439, 524, and 525, as well as
arginines 98, 197, and 428, can all contain significant amounts of modification. All of the
previously identified glycation sites on HSA (e.g.., the N-terminus, K199, K281, K439,
K525 [26,27,29]) were found to be modified in the glycated HSA samples that were
examined in this study. In addition, a known site for advanced glycation end products in
HSA (i.e., R428) [45] was also found to have significant amounts of modification in this
study. This information indicated that the results from this study gave good agreement with
previous reports examining the glycation of HSA. Quantitative studies using 16O/18O-
labeling and mass spectrometry are currently being conducted to more accurately determine
the extent of these modifications.
A unique feature of this study was that a semi-quantitative analysis indicated that the
modification pattern of HSA changed with the total extent of glycation. For example, K199
and R197 were found to be modified in all three stages of glycation, with the predominant
modifications on these residues shifting from FL (K199) and 3-DG-H1 or THP (R197) in
the HSA-2 sample to Pyr (K199) and IB (R197) in the HSA-4 and HSA-5 samples.
Similarly, modifications at R428 were found in all three stages of glycation, with this
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residue forming AFGP, 3-DG-H1, or THP in the HSA-2 sample, these same modifications
plus G-H1 or Arg-P in the HSA-5 sample, and MG-H1 in the HSA-4 sample. K199 and
R197 are both located in Sudlow site I on HSA and R428 is located in Sudlow site II, which
indicates that drug-protein interaction at these two regions may, in turn, also depend on the
level of glycation.
Comparison of the data obtained in this report with previous binding studies was used to
demonstrate the physiological and pathological implications of these results [39,50,51]. This
comparison suggested that the changes in binding affinity seen for drugs such as
acetohexamide with in vitro glycated HSA can be affected by both the level of glycation and
the glycation pattern of HSA. The fact that the glycation pattern and types of modification
changed at different levels of glycation indicates that these changes may lead to changes in
drug interactions with HSA during diabetes and with the extent of control for this disease.
By using this work with in vitro glycated HSA as an initial reference point, further work
using 16O/18O-labeling in mass spectrometry and/or work with in vivo glycated HSA is now
being conducted to more fully characterize the nature and extent of these changes in
structure and drug interactions. Preliminary results from these ongoing studies indicate that
R98, R197, K199, K276, K281, K286, and R428 are all modified within in vivo glycated
HSA from patients with moderate to advanced diabetes, which is consistent with the semi-
quantitative results provided in this report. In addition, many modifications found in these in
vivo glycated HSA samples are identical to the modifications noted here for the HSA-4
sample. Tandem mass spectrometry is also being used to verify the presence of some of the
modifications detected in this report for glycated HSA (e.g., this approach has already
verified the presence of CEL at K281, FL-2H2O at K286, Pyr at K205, and variants of FL at
K557, K560, and K564, as determined in this study by using mass spectrometry and
computational methods). The data provided in this current report and these future studies
should provide valuable information that will lead to a better understanding of how drug
transport and binding in blood can change during diabetes. This information, in turn, is
expected to eventually lead to the development of improved strategies based on personalized
medicine for the selection of drugs and drugs dosages for the treatment of diabetes.
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List of Abbreviations
AFGP 1-alkyl-2-formyl-3,4-glycosyl-pyrrole
AGE advanced glycation end product
ArgP argpyrimidine
CEL Nå-carboxyethyl-lysine
CHCA α-cyano-4-hydroxycinnamic acid
CML Nå-carboxymethyl-lysine
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3-DG-H1 Nå-[5-(2,3,4-trihydroxybutyl)-5-hydro-4-imidazolon-2-yl]ornithine
DHB 2,5-dihydroxybenzoic acid; fractional accessible surface area (FAS)
FAS fractional accessible surface area
FL fructosyl-lysine
G-H1 Nå-(5-hydro-4-imidazolon-2-yl)ornithine
HSA human serum albumin
IB imadazolone B
MALDI-TOF MS matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry
MG-H1 Nå-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine
Pyr pyrraline
TFA trifluoroacetic acid
THP tetrahydropyrimidine
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Figure 1.
Measured level of glycation for HSA, as measured by a fructosamine assay and obtained as
a function of time for the reaction of 42 g/l HSA with 15 mmol/l glucose at pH 7.4 and 37
°C. The error bars represent a range of ± 1 S.D.
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Figure 2.
Structure of HSA showing the most likely sites for glycation-related modifications, as based
on a semi-quantitative comparison of the data obtained in this study. The regions that were
found to have the highest levels of modification are highlighted. The amino acids that
contained the highest amounts of modification within these regions are also shown.
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Table 2
Suspected modification sites found on various samples of in vitro glycated HSA
Digest Residues Relevant Amino Acid Suspected Modification Sitesa
HSA-2
Trypsin 1–10 N+, K4, R10 N+ (FL-1H2O) + K4 (AFGP)
Trypsin 275–286 K276, K281, K286 K276 & K281 (FL & FL-1H2O)
Trypsin 539–557 or 542–560 K541, K545, K557
K545, K557, K560
K545 & K557 (FL-2H2O & FL-2H2O) or (FL-1H2O & Pyr)
K545 & K557 (FL-2H2O & Pyr) or (FL + CEL)
Glu-C 278–292 K281, K286 K281 & K286 (FL & CEL) or (FL-2H2O & Pyr)
Glu-C 83–100 K93, R98 K93 (FL-2H2O) or K93 & R98 (CEL & MG-H1)
Glu-C 566–585 or 168–188 K573, K574
K174, K181, R186
K573 and K574 (AFGP*2)
K174 & R186 (FL & ArgP)
Lys-C 196–205 K199, K205, R197 K199 & R197 (FL & 3-DG-H1/THP)
Lys-C 414–432 K414, K432, R428 K414 & R428 (FL-1H2O & AFGP) or K414 & R428 (AFGP
and 3-DG-H1/THP)
HSA-5
Trypsin 520–525 K524, K525, R251 R521 & K524 (Pyr & G-H1)
Trypsin 275–286 K276, K281, K286 K276 & K281 (FL & FL-1H2O)
Glu-C 281–294 K281, K286 K281 & K286 (FL-2H2O & CEL)
Glu-C 426–442 K432, K436, K439, R428 R428 & K439 (G-H1 & Pyr) and (ArgP & CEL)
Glu-C 189–208 K190, K195, K199, K205,
R197
K199 & R197 (Pyr & IB)
Lys-C 5–20 K12, K20, R10 K12 (FL)
Lys-C 414–432 K414, K432, R428 K414 & R428 (FL-1H2O & AFGP) or (AFGP & 3-DG-H1/
THP)
Lys-C 525–534 K525, K534 K525 (FL-1H2O)
HSA-4
Trypsin 1–12 N+, K4, K12, R10 N+ & K4 (CEL & FL-2H2O) or N+ & R10 (FL-1H2O &
MG-H1)
Trypsin or 200–212
or 403–413
K205, K212, R209
K413, R410
K205 & R209 (CML & ArgP)
K413 or R410 (AFGP)
Trypsin 198–209
or 182–195
or 206–218
K199, K205, R209
K190, K195, R186
K212, R209, R218
K199 & K205 AFGP, (FL & Pyr), or (FL-1H2O+FL-2H2O)
R186 & K190 (ArgP & Pyr)
R209 & K218 (FL-1H2O & MG-H1)
Trypsin 258–274 K262, K274 K262 (FL-1H2O)
Glu-C 312–321 K313, K317 K313 & K317 (AFGP & AFGP)
Glu-C 557–571 K557, K560, K564 K560 & K564 (FL & CML)
Glu-C 426–442 K432, K436, K439, R428 K439 (FL) or R428 & K439 (Pyr+MG-H1)
Glu-C 83–100 K93, R98 K93 (FL-2H2O) or K93 (CEL) & R98 (MG-H1)
Glu-C 189–208 K190, K195, K199, K205,
R197
K199 & R197 (Pyr & IB)
a
The most likely modification sites, which were identified based on computational and structural data, are given in bold. The abbreviations for the
types of glycation are defined in Table 1.
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Supplemental Information 
 The following information includes a figure summarizing the sequence coverage for the 
control and glycated HSA samples (see Figure 1s). A table is also provided that summarizes the 
calculated pKa and fractional accessible surface area (FAS) values for different amino acid side 
chains on HSA (see Table 1s).  Along with this table is provided a description of how the 
assignment of glycation sites was made in this study based on local acid-base catalysis and the 
estimated pKa and FAS values for the various residues on HSA.  
 
Assignment of highly reactive sites for glycation based on computational data 
 The location of lysine residues versus other basic amino acids, particularly other lysines 
or histidine residues is thought to be due to localized acid-base catalysis [1].  Lysine-lysine or 
lysine-histidine α-carbon distances were computed in this study from the crystal structure of 
HSA (i.e., PDB file 1AO6) [2] by using the molecular modeling program Visual Molecular 
Dynamics (VMD) [3].  
  The pKa of a given lysine/arginine was also used an indicator of reactivity because a 
deprotonated state for these residues is needed for the formation of early or advanced stage 
glycation products.  The pKa values for such residues were estimated in this report by using 
PROPKA [4], which is a program that calculates perturbations in the experimentally determined 
amino acid pKa values due to charge-charge interactions, hydrogen-bonding, and desolvation 
effects.  Residues with large FAS values, as calculated by using the program VADAR [5], would 
be more exposed to the solvent; this exposure would be expected in turn to allow for more 
interactions between reactants that might lead to glycation products on lysine or arginine 
residues.  The calculated pKa and FAS values for lysine and arginines that were suspected to be 
modified to form glycation products are summarized in Table 1s. 
References 
[1]  Iberg N, Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. J Biol Chem 
1986;261:13542-5. 
[2]  Sugio S, Kashima A, Mochizuki S, Kobayashi K. Crystal structure of human serum albumin 
at 2.5 Å resolution. Protein Eng 1999;12:439-46. 
[3]  Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph 
1996;14:33-8. 
[4]  Li H, Robertson AD, Jensen JH. Very fast empirical prediction and rationalization of protein 
pKa values. Proteins 2005;61:704-21. 
[5]  Willard L, Ranjan A, Zhang H, et al. VADAR: a web server for quantitative evolution of 
protein structure quality. Nucleic Acids Res 2003; 31:3316-9. 
Figure 1s. Sequence coverage observed for the control HSA and the glycated HSA samples.  
The sequence coverage obtained when all four HSA samples were considered is 
shown in bold.  The sequence coverage obtained for the HSA control sample is 
shown in capital letters, the coverage obtained for the HSA-2 sample is 
underlined, the coverage obtained for the HSA-4 sample is highlighted, and the 
coverage obtained for the HSA-5 sample is indicated with a line over the 
sequence.  Peptides that were associated with modification sites were factored 
into the sequence coverage that was obtained for all three HSA samples.   
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Figure 1s. 
Table 1s. Calculated pKa and FAS values for amino acids which are believed to be modified by 
the glycation of HSA  
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